Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $35.75.

A number of brokerages have commented on ODTX. Wall Street Zen downgraded shares of Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 20th. Oppenheimer reissued an “outperform” rating and issued a $40.00 price target on shares of Odyssey Therapeutics in a research note on Thursday, June 18th. TD Cowen started coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They issued a “buy” rating on the stock. Zacks Research raised shares of Odyssey Therapeutics to a “hold” rating in a research report on Wednesday, June 3rd. Finally, Wedbush started coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 price objective on the stock.

Institutional Trading of Odyssey Therapeutics

A hedge fund recently bought a new position in Odyssey Therapeutics stock. Citadel Advisors LLC bought a new stake in Odyssey Therapeutics, Inc. (NASDAQ:ODTX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 222,450 shares of the company’s stock, valued at approximately $4,162,000. Citadel Advisors LLC owned approximately 0.46% of Odyssey Therapeutics as of its most recent SEC filing.

Odyssey Therapeutics Stock Performance

Shares of NASDAQ ODTX opened at $24.51 on Thursday. The stock has a market cap of $1.18 billion and a PE ratio of -3.62. Odyssey Therapeutics has a 12-month low of $15.10 and a 12-month high of $29.05. The company’s 50-day simple moving average is $20.98.

Odyssey Therapeutics (NASDAQ:ODTX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share (EPS) for the quarter. On average, research analysts anticipate that Odyssey Therapeutics will post -5.99 earnings per share for the current fiscal year.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.